(Bristol-Myers Squibb's package insert for Taxol (paclitaxel) injection,http://packageinserts.bms.com/pi/pi_taxol.pdf). The clinically recommended doses of Taxol® are 135–175mg/m2intravenously administered over a 3h infusion every 3weeks. This dose includes also the injection of ~22–29g...
Taxol (package insert). Princeton, NJ: Bristol-Myers Squibb Co; 2011. Taxotere (package insert). Bridgewater, NJ: sanofi-aventis US LLC; 2013. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980;77:1561–5. Article CAS PubMed ...
which became the first FDA-approved siRNA therapeutic in 2018. We note, however, that the siRNA component interacts with the lipid’s headgroup in the case of patisiran and thus, unlike in our system, the active ingredient has no direct interactions with the polyunsaturated...
In 1992, paclitaxel was approved by the US Food and Drug Administration (FDA) for the treatment of ovarian cancer. In 1996, a study of the Gynecologic Oncology Group (GOG) showed that paclitaxel-cisplatin was superior in terms of survival to the cyclophosphamide-cisplatin regimen as upfront the...